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Summary
Background Influenza and other respiratory viruses promote Streptococcus pneumoniae proliferation in the upper 
respiratory tract. We sought to investigate for what we believe is the first time, the effect of intranasal live attenuated 
influenza vaccine (LAIV) on nasopharyngeal S pneumoniae density in a low-income to middle-income country 
population with high pneumococcal carriage rates.
Methods In an open-label, randomised, controlled trial in The Gambia, 330 healthy children aged 24–59 months were 
randomly assigned 2:1 to receive one trivalent LAIV dose at enrolment (day 0, intervention) or at the end of active 
follow-up (day 21, control). The investigator team were initially masked to block size and randomisation sequence to 
avoid allocation bias. Group allocation was later revealed to the investigator team. The primary outcome was PCR-
quantified day 7 and 21 pneumococcal density. Asymptomatic respiratory viral infection at baseline and LAIV strain 
shedding were included as covariates in generalised mixed-effects models, to assess the effect of LAIV and other 
variables on pneumococcal densities. The study is registered at ClinicalTrials.gov, NCT02972957, and is closed to 
recruitment.
Findings Between Feb 8 and April 12, 2017, and Jan 15 and March 28, 2018, of 343 children assessed for eligibility, 
213 in the intervention group and 108 in the control group completed the study and were included in the final analysis. 
Although no significant differences were seen in pneumococcal carriage or density at each timepoint when comparing 
groups, changes from baseline were observed in the LAIV group. The baseline S pneumoniae carriage prevalence was 
high in both LAIV and control groups (75%) and increased by day 21 in the LAIV group (85%, p=0·0037), but not in 
the control group (79%, p=0·44). An increase in pneumococcal density from day 0 amounts was seen in the LAIV 
group at day 7 (+0·207 log₁₀ copies per µL, SE 0·105, p=0·050) and day 21 (+0·280 log₁₀ copies per µL, SE 0·105, 
p=0·0082), but not in the control group. Older age was associated with lower pneumococcal density (−0·015 log₁₀ copies 
per µL, SE 0·005, p=0·0030), with the presence of asymptomatic respiratory viruses at baseline (+0·259 log₁₀ copies 
per µL, SE 0·097, p=0·017), and greater LAIV shedding at day 7 (+0·380 log₁₀ copies per µL, SE 0·167, p=0·024) 
associated with higher pneumococcal density. A significant increase in rhinorrhoea was reported in the LAIV group 
compared with the control group children during the first 7 days of the study (103 [48%] of 213, compared with 25 [23%] 
of 108, p<0·0001), and between day 7 and 21 (108 [51%] of 213, compared with 28 [26%] of 108, p<0·0001).
Interpretation LAIV was associated with a modest increase in nasopharyngeal pneumococcal carriage and density in 
the 21 days following vaccination, with the increase in density lower in magnitude than previously described in the 
UK. This increase was accelerated when LAIV was administered in the presence of pre-existing asymptomatic 
respiratory viruses, suggesting that nasopharyngeal S pneumoniae proliferation is driven by cumulative mixed-viral 
co-infections. The effect of LAIV on pneumococcal density is probably similar to other respiratory viral infections in 
children. Our findings provide reassurance for the use of LAIV to expand influenza vaccine programmes in low-
income to middle-income country populations with high pneumococcal carriage.
Funding Wellcome Trust.
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Introduction
Streptococcus pneumoniae is a leading cause of respiratory 
tract infections (RTIs), meningitis, and sepsis globally.1 
The highest burden of pneumococcal disease is 
found in children from low-income and middle-income 
countries (LMICs).1 Nasopharyngeal colonisation with 
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S pneumoniae is common and usually asymptomatic. 
However, S pneumoniae colonisation represents a 
necessary precursor to invasive pneumococcal disease 
and a source of pneumococcal transmission between 
individuals.2 Higher pneumococcal densities are asso-
ciated with pneumococcal disease, although pneu-
mococcal density thresholds that result in higher risk of 
disease are not defined.3
Viral-bacterial co-infections are commonly observed in 
RTIs and associated with greater disease severity. Increased 
risk of secondary pneumococcal pneumonia following 
influenza infection is well documented. Influenza virus 
infection has been shown to enhance acquisition, 
proliferation, and transmission of S pneumoniae in the 
upper respiratory tract (URT).4 Although the underlying 
mechanisms are not exhaustively defined, existing evidence 
Research in context
Evidence before this study
We searched PubMed and Web of Science for research articles 
published in English up to April 7, 2021 with the terms: 
“Streptococcus pneumoniae” OR “pneumococcus” AND 
“colonisation” OR “colonisation density” OR “bacterial load” 
AND “live attenuated influenza vaccine” OR “asymptomatic 
influenza infection” OR “asymptomatic viral infection”. 
This search identified five studies on the effect of live 
attenuated influenza vaccine (LAIV) or asymptomatic 
influenza−viral infection on S pneumoniae colonisation 
dynamics. The first study used a murine model to investigate 
the effect of LAIV on nasopharyngeal S pneumoniae and 
Staphylococcus aureus densities, showing increased bacterial 
loads for both following LAIV. The second study was a 
randomised, clinical trial in children aged 2–4 years from the 
UK, examining the effect of LAIV on upper respiratory tract 
colonisation with S pneumoniae and other bacteria. This study 
found a six-times increase in pneumococcal colonisation 
density at 28 days following one dose of LAIV in children 
colonised with S pneumoniae at baseline (increase from 
2687 copies per mL at baseline to 16687 copies per mL at day 
28). The third study was a longitudinal study in children aged 
between 48 and 96 months in the USA, which showed 
increased colonisation densities of S pneumoniae in the upper 
respiratory tract during symptomatic and asymptomatic 
respiratory viral infections. The fourth study was a cross-
sectional prospective study investigating nasopharyngeal 
carriage of S pneumoniae and other bacteria among children in 
Greece, aged 3 months to 6 years old, presenting with and 
without symptomatic respiratory symptoms. This study 
reported that carriage prevalences were significantly higher in 
symptomatic compared with asymptomatic children for 
S pneumoniae (37·1% compared with 23·6%). The fifth study 
consisted of two randomised, control trials in adults, which 
used a human co-challenge model with LAIV and S pneumoniae 
in the UK. The first trial investigated pneumococcal density in 
adults who were randomly assigned to receive LAIV or placebo 
before challenge with S pneumoniae 3 days later. In this trial, 
a ten-times increase in S pneumoniae densities was observed by 
day 9 in LAIV recipients but not in the control group. In the 
second trial, adults were first challenged with S pneumoniae 
before receiving LAIV or placebo 3 days later. This study 
paradoxically observed reduced S pneumoniae densities in 
adults in the LAIV group. We did not find any published studies 
from low-income and middle-income countries (LMICs) or 
with high pneumococcal carriage prevalences, investigating 
the effect of LAIV or asymptomatic viral infections on 
S pneumoniae colonisation dynamics.
Added value of this study
To the best of our knowledge, our study is the first longitudinal, 
randomised, controlled trial reporting the effect of LAIV and 
asymptomatic viral infections on nasopharyngeal colonisation 
and density of S pneumoniae in a low-income to middle-income 
country population with high pneumococcal carriage 
prevalences. Our results show that LAIV leads to an increase in 
nasopharyngeal pneumococcal density in this population, 
similar to the effect caused by asymptomatic viral infections in 
this cohort. Although, to a much lower magnitude (1·78 times 
the original magnitude) than previously shown in the study of 
UK children given LAIV (six times). We also report a small 
increase in the proportion of children with pneumococcal 
carriage 21 days after receiving LAIV (75–85%). Additionally, 
we show that LAIV administered in the presence of pre-existing 
asymptomatic respiratory viruses accelerates pneumococcal 
proliferation in the nasopharynx. Our study is, we believe, 
the first to show that LAIV leads to modest increases 
in S pneumoniae colonisation and density in children residing in 
an area of high pneumococcal carriage, and to a degree not 
dissimilar to fluctuations seen due to repeated asymptomatic 
respiratory viral infections.
Implications of all the available evidence
Our study contributes to the existing knowledge highlighting 
the importance of asymptomatic viral infections on 
S pneumoniae colonisation densities in the nasopharynx, as 
well as the specific effect of LAIV on S pneumoniae dynamics in 
young children. Asymptomatic viral infections are common 
and could be an important contributing factor to high 
colonisation densities and consequently transmission rates, 
even after introduction of pneumococcal vaccines in LMICs. 
Strategies to reduce pneumococcal carriage, transmission 
rates, and disease should also consider interventions to reduce 
respiratory viral infections, especially in at risk populations 
including children. Our data provides evidence that the effect 
of LAIV on S pneumoniae density in children residing in an area 
of high pneumococcal carriage is modest and supports the 
wider rollout of LAIV in LMICs to help reduce the burden of 
influenza-related morbidity and mortality.
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suggests that influenza viruses induce mucosal epithelial 
disruption, leading to elevated production of both pro-
inflam matory and anti-inflammatory cytokines and 
impaired macrophage phagocytic function.5 This provides 
a con ducive environment for proliferation and invasion of 
S pneumoniae, and increases host susceptibility to severe 
lower RTIs and invasive disease.5,6
Live attenuated influenza vaccine (LAIV) is adminis-
tered as a nasal spray for the prevention of influenza 
infection and is safe and highly efficacious in young 
children.7 LAIV strains are able to replicate in the URT 
similar to wild-type influenza viruses; however, their 
cold-adapted and temperature sensitive nature prevents 
replication in the lower respiratory tract.8 LAIV has been 
shown to increase pneumococcal colonisation densities 
in murine models and in one study of children from a 
high-income setting, where a six-times increase from 
baseline was observed.9,10 These effects are similar to 
wild-type influenza infection, but without progression to 
clinical symptoms or disease.9,11 These data highlight the 
potential indirect consequences of LAIV on S pneumoniae 
density in the URT, as well as the potential importance 
of paucisymptomatic or asymptomatic viral infection 
on colonisation dynamics of residing nasopharyngeal 
bacteria such as S pneumoniae.
There are no data available on the effect of LAIV on 
nasopharyngeal S pneumoniae proliferation in children 
from LMICs, where in many settings high rates of 
pneumococcal carriage and disease are seen. Despite 
high uptake of pneumococcal conjugate vaccines (PCVs), 
pneumococcal carriage rates in The Gambia in children 
younger than 5 years continues to be over 70%, primarily 
with non-PCV serotypes. The burden of influenza in 
LMICs is not well known due to lack of robust 
surveillance data in these settings, but influenza-related 
mortality in sub-Saharan Africa is estimated to be higher 
compared with other regions.12 Routine influenza 
vaccination programmes for at-risk groups such as 
children younger than 5 years are not in place in most of 
sub-Saharan Africa. LAIV could be a good option to 
address this gap in LMICs, given its needle-free delivery, 
lower manufacturing costs and high acceptability.13–15 
Evaluating any potential unwanted effects such as the 
effect on nasopharyngeal S pneumoniae proliferation are, 
therefore, vital. We describe results from a randomised, 
controlled trial to explore the effect of LAIV on 
pneumococcal colonisation densities in children aged 
24–59 months in The Gambia, in addition to examining 
the contribution of asymptomatic respiratory viral 
infections to these viral–bacterial interactions.
Methods
Study design and participants
We did an open-label, phase 4 RCT (NCT02972957) across 
2 years (2017 and 2018). Recruiment was done outside the 
peak influenza transmission season in The Gambia, which 
coincides with the rainy season during June to October 
each year.16 We have previously shown that all respiratory 
viral infections are lower during the dry season in 
The Gambia, although year round transmission of many 
viruses still occurs, in particular human rhinoviruses.16 
Participants were healthy, influenza vaccine naive children 
aged 24–59 months from a peri-urban community setting 
(Sukuta), with no history of respiratory infections within 
the past 14 days (full inclusion and exclusion criteria in the 
appendix pp 2–3).
The study was approved by The Gambia Government 
and UK Medical Research Council joint ethics committee 
and the Medicines Control Agency of The Gambia. Parents 
provided written or thumbprinted informed consent for 
their children to participate. If parents were not English 
literate, an impartial witness was present during the 
informed consent discussion done in a local language, 
who signed to confirm completeness of the consent 
provided. The trial protocol is included in the appendix.
Randomisation and masking
Children were randomly assigned to receive LAIV on the 
day of enrolment (day 0) or delayed until day 21 (control 
group). Block randomisation stratified by sex was done 
by use of sealed opaque envelopes and a computer-
generated randomisation sequence pre-prepared by an 
independent statistician not involved in the rest of the 
study. The investigator team was masked to block size 
and randomisation sequence to avoid allocation bias. 
Group allocation was revealed on opening the envelope, 
cross-checked and co-signed by a second individual. As 
an open-label study, from this point on, the investigator 
team were aware of group allocation. Because of the need 
to carry out LAIV quantitative PCR (qPCR) on samples in 
the LAIV group only, group allocation was also revealed 
to the local laboratory team after recruitment. The 
external laboratory where pneumococcal qPCR was done 
was masked to group allocation until analysis.
Procedures
Northern hemisphere Russian-backbone trivalent LAIV 
(Nasovac-S, Serum Institute of India, Pune, India) was 
used in both years, containing 2009 pandemic 
H1N1 (A/17/California/2009/38 in 2017 and A/17/New 
York/15/5364 in 2018), H3N2 (A/17/Hong Kong/2014/8296), 
and influenza B-Victoria (B/Texas/02/2013) viruses. 
Nasopharyngeal samples were collected by means of 
flocked paediatric swabs stored in RNAprotect (Qiagen, 
UK) at day 0 (pre-LAIV), day 2, day 7, and day 21. Samples 
were processed within 4 h of collection and stored at 
−70°C until further processing. The occurrence of adverse 
events since the last visit were recorded at day 7 and day 21.
DNA was extracted from nasopharyngeal by means 
of the AGOWA Mag Mini DNA extraction kit 
(LGC Genomics, Berlin, Germany) in combination with 
phenol–bead beating as previously described.17 A 
quantitative real-time PCR targeting the conserved 
autolysin (lytA) gene of S pneumoniae was used to detect 
See Online for appendix
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and quantify pneumococcal loads in all samples, with a 
cycle threshold (Ct) value of less than 40 considered 
positive.18 Bacterial quantities were estimated by means 
of a standard curve prepared from six 1:10 serial dilutions 
of a S pneumoniae strain of known concentration, ranging 
from 1 ng/µL to 0·00001 ng/µL (441 000 to 4·41 genome 
copies per µL).
A multiplex respiratory virus real-time PCR was done as 
previously described on all day 0 samples to detect 
influenza A, influenza B, respiratory syncytial virus 
(RSV) A, RSV B, human parainfluenza viruses (HPIV) 1–4, 
human metapneumovirus, adenovirus, seasonal corona-
viruses (CoV; 229E, OC43, NL63), and human rhinovirus.19 
Day 7 samples from control group participants were also 
tested for a post-hoc analysis. Shedding of LAIV strains 
was assessed on day 2 and day 7 by means of a monoplex 
RT-PCR, with haemagglutinin-specific primers and probes 
as previously described.20
Outcomes
The density of S pneumoniae as established by quantitative 
PCR at day 7 and day 21, compared with day 0, was 
defined as a primary outcome in the clinical trial protocol. 
Exploratory outcomes were LAIV strain shedding (day 2 
and day 7) and the prevalence of asymptomatic respiratory 
viruses at baseline.
Statistical analysis
Sample size was calculated on the basis of previously 
described estimates by means of a stochastic-simulation 
approach that takes into account variance in bacterial 
prevalence and densities.21 At a baseline pneumococcal 
carriage prevalence of 75% and accounting for 10% loss 
to follow-up, 220 LAIV-immunised participants would 
provide >99% power at an alpha of 0·05 to detect a 
two times increase in colonisation density following 
LAIV.
Children completing their day 21 visit with available 
samples were included in the final modified intention-to-
treat analysis. χ² or Fisher’s exact tests were used to 
compare S pneumoniae carriage prevalence and adverse 
events between groups at each timepoint. In addition, 
generalised logistic mixed-effect models were used to 
explore the change in carriage prevalence over time 
within each group.
Pneumococcal colonisation densities were transformed 
to log₁₀ +1 copies per µL for analysis. Differences in 
colonisation densities between groups per timepoint 
were assessed by means of the Mann-Whitney U test (for 
data distributions see the appendix p 10). Generalised 
linear mixed-effect models were used to study the 
association between colonisation densities (response 
variable), LAIV administration, and other covariates, 
with a random effect on participants. In order to capture 
the effect of new S pneumoniae acquisition during the 
study period, all participants were included and not just 
those with positive pneumococcal PCR at baseline. 
A multivariable model was initially built containing all 
covariates of interest and possible interactions, including 
those suspected to be associated with S pneumoniae 
Figure 1: Trial profile
Overview of participants recruited and retained in the study. Recruitment in 2017 (A). Recruitment in 2018 (B). Children randomly assigned to the LAIV group 
received one dose of Russian-backbone trivalent LAIV containing either A/17/California/2009/38 in 2017 or A/17/New York/15/5364 in 2018 at day 0. H3N2 strain 
and influenza B lineages included in the vaccine remained consistent across the 2 years. LAIV=live attenuated influenza vaccine.
50 randomly assigned to
LAIV at day 21
48 completed study
2 missed study visits and
withdrew consent
161 participants assessed for eligibility
152 randomly assigned 2:1 LAIV 
at day 0:day 21 groups
9 ineligible
7 acute respiratory illness in 
last 14 days
1 other acute illness
1 older than 59 months
102 randomly assigned to
LAIV at day 0
95 completed study
7 missed study visits and
withdrew consent
60 randomly assigned to
LAIV at day 21
60 completed study
182 participants assessed for eligibility
178 randomly assigned 2:1 LAIV at 
day 0:day 21 groups
4 ineligible
1 severe weight-for-height 
malnutrition
3 acute respiratory illness 
in last 14 days
118 randomly assigned to
LAIV at day 0
118 completed study
A 2017 A 2018
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colonisation densities to understand vaccine effects, 
potential con founders, and their estimated effect sizes. 
Stepwise backwards selection was used to arrive at the 
most parsimonious model, with comparisons between 
models done by means of likelihood ratio tests 
(appendix p 3). Covariates with a p value of <0·05 were 
deemed significant. Additional exploratory analyses were 
done by fitting a series of stratified, post-hoc models to 
obtain more detailed insight into the relationship 
between pneumococcal density and the same covariates 
in specific groups (eg, LAIV recipients or controls). 
All analyses were done by means of R software 
(version 3.5.1).No data monitoring committee was used. 
The study is registered at ClinicalTrials.gov, NCT02972957.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report.
Results
Between Feb 8 and April 12, 2017, 178 children of 182 
assessed for eligibility were recruited and randomly 
assigned to receive LAIV at day 0 (LAIV group; n=118) or 
day 21 (control group; n=60). Between Jan 15 and 
March 28, 2018, 152 children of 161 assessed for eligibility 
were randomly assigned to the LAIV (n=102) or control 
(n=50) groups. All children in 2017 and 143 (94%) in 2018 
completed the study (figure 1). All study visits were 
within protocol-defined windows (+1 day for day 2, 
+7 days for day 7, +7 days for day 21) and 96% were on the 
exact visit day. In the LAIV group, samples were available 
for lytA PCR in 211 of 213 samples at day 0 and all 
samples at day 7 and day 21, whereas in the control 
group, samples from all 108 children were available from 
all three timepoints.
Baseline characteristics were similar between the 
two groups, with a pneumococcal carriage prevalence 
of 74·9% at day 0 (table 1). Of the children in the LAIV 
group who had D0 samples available for respiratory viral 
RT-PCR, 67 (33%) of 205 had an asymptomatic viral 
infection, compared with 41 (39%) of 104 in the control 
group. Overall, 82 (76%) of 108 of these infections were 
due to a rhinovirus (table 1).
The difference in prevalence of S pneumoniae 
colonisation was not significant between groups at day 7 
(174 [82%] of 213 LAIV and 83 [77%] of 108 control, 
p=0·38) or day 21 (180 [85%] of 213 LAIV and 85 [79%] 
of 108 control, p=0·25, table 2). However, by means 
of a logistic mixed-effect regression model to take 
into account within-individual changes over time, the 
presence of pneumococcal colonisation was higher at 
day 7 (p=0·042) and day 21 (p=0·0037) compared with 
day 0 in the LAIV group (table 3), but not in the control 
group (p=0·70 for day 7 vs day 0; p=0·44 for day 21 vs 
day 0, appendix p 4). Similarly, when comparing median 
pneumococcal density between each group at each 
timepoint, no significant differences were observed 
(table 2). Generalised linear mixed-effect regression 
models were done to study the effect of LAIV and other 
covariates on the dynamics of pneumococcal density. 
We observed a significant association between LAIV 
administration at day 0 and higher S pneumoniae 
colonisation density during the study period (p=0·0097, 
appendix p 4), adjusting for year of recruitment, presence 
of baseline asymptomatic viruses, age, and household 
cooking practice. Increases in S pneumoniae density were 
Live attenuated influenza 
vaccine (n=213)
Control (n=108)
Age, months 36·4 (28·4–42·4) 35·1 (27·6–40·3)
Sex
Male 116 (55%) 58 (54%)
Female 97 (46%) 50 (46%)
Baseline asymptomatic virus present* 67 (33%) 41 (39%)
Adenovirus 3 (4%) 3 (7%)
Seasonal coronaviruses 7 (10%) 3 (7%)
Parainfluenza 1 2 (3%) 4 (10%)
Parainfluenza 1 and seasonal coronaviruses 1 (1%) 0
Parainfluenza 1 and rhinovirus 1 (1%) 0
Parainfluenza 3 0 1 (2%)
Rhinovirus 50 (75%) 25 (61%)
Rhinovirus and adenovirus 1 (1%) 3 (7%)
Rhinovirus and seasonal coronaviruses 1 (1%) 1 (2%)
Respiratory syncytial virus A 1 (1%) 0
Respiratory syncytial virus B 0 1 (2%)
Presence of smoker in the house 51 (24%) 21 (19%)
Outdoor cooking area† 189 (89%) 97 (90%)
Baseline Streptococcus pneumoniae colonisation‡ 158 (75%) 81 (75%)
Data are median (IQR) or n (%). Percentages might not sum to 100 due to rounding. *205 children in LAIV group and 
104 children in control group had day 0 data available for respiratory viral co-infection. These data were not available 
for eight children in the LAIV group and four children in the control group due to the lack of sample availability for 
respiratory viral assays. Percentages given for individual or combinations of viruses detected use the total number 
of children with asymptomatic viruses detected for each group as the denominator. †Cooking inside (under a roof) 
compared with cooking using an indoor kitchen. Note that 99% of children lived in households where wood or 
charcoal was the primary fuel used to cook regardless of location of cooking. ‡Streptococcus pneumoniae detection was 
done by lytA PCR; S pneumoniae positive samples were defined as having a cycle threshold value of <40 on lytA PCR. For 
the LAIV group, 211 of 213 day 0 samples were available for testing.
Table 1: Baseline characteristics
LAIV group Control group p value*
S pneumoniae carriage prevalence
Day 0 158/211 (75%)† 81/108 (75%) 1·00
Day 7 174/213 (82%) 83/108 (77%) 0·38
Day 21 180/213 (85%) 85/108 (79%) 0·25
S pneumoniae colonisation density, log₁₀ copies per µL
Day 0 1·17 (0·02–2·08) 1·21 (0·06–2·08) 0·73
Day 7 1·43 (0·44–2·32) 1·18 (0·05–2·32) 0·084
Day 21 1·24 (0·34–2·49) 1·34 (0·16–2·49) 0·80
Data are n (%) or median (IQR). *Comparisons of carriage rates between groups 
done using the χ² test. Cross-sectional comparisons of S pneumoniae density 
between groups at each timepoint were done using the Mann-Whitney U test.
Table 2: Streptococcus pneumoniae carriage rate and colonisation density 
during study period
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also seen with baseline asymptomatic viral infection 
(p=0·017), younger age (p=0·0030), day 21 of study 
(p=0·0015), and recruitment in 2018 (p=0·0091). 
However, a significant interaction was seen between year 
of recruitment and group (appendix p 4, p=0·016).
To investigate this interaction, generalised mixed-effect 
models were stratified by study group (LAIV or control, 
table 4; appendix p 5). A significant increase in 
pneumococcal density at day 21 was seen in the LAIV 
group (+0·280 log₁₀ copies per µL, SE 0·105, p=0·0082, 
table 2), adjusting for year of recruitment, presence 
of asymptomatic viruses at baseline, age, and household 
cooking practice; but not in the control group 
(appendix p 5). No effect of year of recruitment was 
seen in the LAIV group (p=0·61, table 4), but 
greater S pneumoniae densities were observed in the 
control group recruited in 2018 compared with 2017 
(+0·402 log₁₀ copies per µL, p=0·018, appendix p 5). 
These differences between control groups recruited 
in 2017 and 2018 were confirmed in generalised mixed-
effects models stratified by year of recruitment 
(appendix pp 5–6).
The presence of an asymptomatic viral infection at 
baseline was associated with higher pneumococcal 
density during the study period in LAIV recipients 
(+0·287 log₁₀ copies per µL, p=0·020, table 4) but not in 
the control group (+0·135 log₁₀ copies per µL, p=0·41, 
appendix p 4). In the LAIV group, the presence of an 
asymptomatic respiratory virus at baseline resulted in an 
earlier peak in pneumococcal density at day 7 (figure 2A).
The greater pneumococcal density in the control 
recruited in 2018 appeared to be seen mainly in children 
with no respiratory viruses detected at day 0, and due to 
an increase between day 7 and day 21 (+0·311 log₁₀ copies 
per µL, SE 0·155, p=0·050, figure 2B and appendix p 6). 
This probably explains the interaction seen in our main 
analysis between group and year on the effect of LAIV 
on pneumococcal density. Because asymptomatic viral 
infections at baseline in control group participants were 
not significantly different in 2017 (24 [40%] of 60) 
compared with 2018 (17 [39%] of 44, p=0·93), we 
hypothesised that this unexpected increase in pneu-
mococcal density in the control group between day 7 
and day 21 in 2018 might have been due to acquisition of 
new respiratory viral infections between day 0 and day 7, 
leading to greater pneumococcal proliferation by day 21. 
Of samples available for testing, 10 (21%) of 48 children 
in the 2017 control group had acquired a new viral 
infection by day 7, compared with 17 (40%) of 42 children 
in the 2018 control group (p=0·07, appendix p 7). 
Overall, (20 [54%] 37) new viral infections were due to a 
rhinovirus infection. The median day 21 pneumococcal 
density in children who acquired a new viral infection 
was 1·93 log₁₀ copies per µL (IQR 0·92–2·65) compared 
with 1·34 log₁₀ copies per µL (0·03–2·15, p=0·12) in 
those who did not. Because of unavailability of day 7 
samples from the LAIV group for further testing, this 
analysis was done by use of only samples from the 
control group.
We next investigated whether the degree of LAIV strain 
viral shedding was a potential driver of the observed 
increase in pneumococcal densities. We have previously 
described the detailed shedding dynamics observed in 
this cohort, with 184 (86%) of 213 children at day 2 and 
154 (72%) of 213 at day 7 shedding at least one strain.22 
Children were categorised as high viral shedders if the 
Ct value in any of the three strains was equal to or below 
the median Ct value of all RT-PCR values at each 
timepoint. Pneumococcal densities among high and low 
day 2 shedders were similar (figure 3A). In a generalised 
linear model including baseline asymptomatic respi-
ratory viruses, year of recruitment and age as covariates, 
high LAIV viral shedding at day 7 was associated with 
Odds ratio 95% CI p value*
Asymptomatic respiratory virus at 
day 0
2·03 0·93–4·43 0·076
Day 7 (vs day 0) 1·82 1·02–3·24 0·042
Day 21 (vs day 0) 2·44 1·34–4·47 0·0037
Age, months 0·96 0·92–0·99 0·030
Household cooking indoors (vs 
outdoors)†
0·49 0·17–1·45 0·20
S pneumoniae detection was done by lytA PCR. *p values for factors associated 
with S pneumoniae carriage prevalence in the live attenuated influenza vaccine 
group are derived from a generalised logistic mixed-effect model, taking into 
account changes within individuals over time. Backwards model selection was 
done as described in the appendix before deciding on variables to include in the 
optimum model. Reference levels for each variable are given within brackets. 
†Cooking inside (under a roof) compared with cooking using an indoor kitchen. 
Note, 99% of children lived in households in which wood or charcoal was the 
primary fuel used to cook regardless of location of cooking.
Table 3: Factors associated with Streptococcus pneumoniae carriage 
prevalence in the live attenuated influenza vaccine group
Change in log₁₀ 
copies per µL
SE p value*
Asymptomatic respiratory virus 
at day 0
+0·287 0·122 0·020
Day 7 (vs day 0) +0·207 0·105 0·050
Day 21 (vs day 0) +0·280 0·105 0·0082
Recruitment in 2018 (vs 2017) −0·059 0·116 0·61
Age, months −0·019 0·006 0·0020
Household cooking indoors (vs 
outdoors)†
−0·290 0·185 0·12
S pneumoniae detection was done by lytA PCR. *p values for factors associated 
with S pneumoniae density in the live attenuated influenza vaccine group are 
derived from a generalised linear mixed-effect model, taking into account 
changes within individuals over time. Backwards model selection was done as 
described in the appendix before deciding on variables to include in the 
optimum model. Reference levels for each variable are given within brackets. 
†Cooking inside (under a roof) compared with cooking using an indoor kitchen. 
Note, 99% of children lived in households in which wood or charcoal was the 
primary fuel used to cook regardless of location of cooking.
Table 4: Factors associated with S pneumoniae colonisation density in 
the live attenuated influenza vaccine group
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higher day 7 pneumococcal density (+0·380 log₁₀ copies 
per µL compared with low viral shedding, SE 0·167, 
p=0·024, figure 3B, appendix p 7). This association was 
not seen between day 2 LAIV shedding and day 7 
pneumococcal density (appendix p 8).
Finally, a significant increase in rhinorrhoea was 
reported in the LAIV group compared with the control 
group children during the first 7 days of the study 
(103 [48%] of 213, compared with 25 [23%] of 108, 
p<0·0001), and between day 7 and 21 (108 [51%] of 213, 
compared with 28 [26%] of 108, p<0·0001). No other 
adverse events were significantly increased in the LAIV 
group (appendix pp 8–9).
Discussion
We report what we believe is the first study exploring the 
effect of LAIV on pneumococcal density in children 
living in an LMIC with a high prevalence of S pneumoniae 
carriage. We found a modest increase in pneumococcal 
density following LAIV administration, supporting our 
initial hypothesis. Although these findings are consistent 
with the only other such study among children in 
the UK,10 the increase in density we observed was less 
(1·78-times the original magnitude by day 21) than the 
six-times increase (at day 28) in genome copies per mL 
reported by Thors and colleagues.22 Furthermore, the 
increase in our study was mainly seen between day 0 
and 7 (1·58-times), consistent with the peak seen in a 
mouse model,9,10 and appeared to be driven by higher 
viral shedding and co-infection with asymptomatic 
respiratory viruses at baseline.
The reasons for this contrast with the study of UK 
children are not entirely clear. Our study used the trivalent 
Russian-backbone LAIV whereas Thors and colleagues 
used a trivalent Ann Arbor LAIV.10 Given the influence of 
the high LAIV shedding on pneumococcal density we 
observed, and the effect of pre-existing influenza 
antibodies on shedding we have previously shown,20 it is 
possible that differences in either LAIV formulation or 
previous influenza history in the two cohorts could have 
played a role. Although it is possible that had we extended 
our timepoints to day 28 we might have seen a similar 
rise, our observed dynamics with the greatest increase 
between day 0 and 7 would suggest otherwise. Finally, 
although comparison of pneumococcal densities across 
the two studies should be done with caution, it is striking 
that our baseline pneumococcal density in the LAIV 
group (1·26 log₁₀ copies per µL or 18 197 copies per mL) 
was higher than that in the UK study even following the 
six-times rise (16 687 copies per mL). Little is known 
about the plausible dynamic range of pneumococcal 
colonisation in the paediatric nasopharynx, but there 
might be limits to how much perturbation is possible if 
density is already very high and at relative equilibrium 
with other microorganisms.
We observed that the presence of an asymptomatic 
respiratory viral infection at baseline was associated with 
an earlier peak and higher pneumococcal densities 
following LAIV. Respiratory viruses are common in 
asymptomatic children,23,24 albeit data are scarce from 
LMICs. In a 52-week household transmission study in 
Utah, 79 (31%) of 254 of viral episodes in 21 children 
younger than 5 years were asymptomatic.23 In a Dutch 
cohort, 250 (83%) of 303 healthy asymptomatic children 
(median age 14·1 months) had at least one respiratory 
virus detected, with rhinovirus being most prevalent.24 
The prevalence of asymptomatic viruses detected in our 
cohort was lower (35%), but in slightly older children 
who were deliberately recruited during the dry season in 
Figure 2: Effect of the presence of asymptomatic respiratory viral infection at baseline on 
Streptococcus pneumoniae densities during the study period in the LAIV group (A) and the control group (B)
LAIV=live attenuated influenza vaccine.
Figure 3: Effect of LAIV viral shedding on Streptococcus pneumoniae densities
Mean densities of S pneumoniae in LAIV recipients stratified by LAIV shedding at (A) day 2 or (B) day 7. High LAIV 
shedding was defined as a Ct value equal to or lower than the median Ct-value in any of the three LAIV strains at each 
timepoint. Values above the median Ct value were classified as low LAIV shedding. All individuals with no shedding 
detected at each timepoint were included in the low shedding group. Note, lower Ct values denote higher amounts of 
virus. LAIV=live attenuated influenza vaccine. Ct=cycle threshold. *A significant association between high day 7 LAIV 
shedding and day 7 pneumococcal density seen in generalised linear models (+0·380 log₁₀ copies per µL compared 
with low LAIV shedding at day 7, p=0·024, appendix p 7), but not between day 2 LAIV shedding and day 7 
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The Gambia when less respiratory viral infections occur. 
Interestingly, the trajectories of pneumococcal density 
during the study were very similar between LAIV 
recipients with no baseline respiratory virus compared 
with control group participants who had asymptomatic 
viruses detected at day 0. This suggests that the effect of 
LAIV on pneumococcal density might be similar to any 
other mild respiratory viral infection. Importantly, our 
findings show that the effect of asymptomatic viruses on 
pneumococcal density is enhanced with cumulative 
infections, whether acquired naturally or introduced in 
attenuated forms such as LAIV. We detected a new 
respiratory viral infection in 27 (30%) of 90 children in 
the control group at day 7 of the study. This highlights 
how frequently the nasopharynx of young children is 
subjected to new viruses and therefore the dynamic 
nature of viral–bacterial interactions that must exist in 
this biological niche. Increases in pneumococcal density 
have been shown in children aged 48–96 months during 
both symptomatic and asymptomatic acute respiratory 
viral infections.25 Another study in children aged 
3 months–6 years old showed pneumococcal carriage 
prevalences to be higher during symptomatic (37·1%) 
compared to asymptomatic (23·6%) respiratory viral 
infections.26
Lastly, LAIV receipt was associated with increased 
rhinorrhoea in our study. Elevated pneumococcal 
colonisation density during episodes of viral rhinitis in 
children can potentially facilitate pneumococcal trans-
mission.22 It is possible that prolonged nasal discharge 
combined with the modest increase in pneumococcal 
density could together increase the chances of pneu-
mococcal transmission in this setting. This could be 
explored in studies specifically measuring S pneumoniae 
acquisition in household members of children receiving 
LAIV.
Our study has several strengths. The randomised, 
controlled design and longitudinal nature allowed us to 
compare bacterial dynamics over time, enabling us to 
quantify the effect of LAIV on pneumococcal density 
while minimising confounding effects. High retention of 
study participants and adherence to study visit dates 
greatly reduced variability. Our study was adequately 
powered to detect at least a 2-times increase in 
pneumococcal density following LAIV. A 1·5–2·0-times 
increase has been suggested as being at the lower end of 
a clinically meaningful increase with respect to enhanced 
transmission potential.21
Our study has limitations. We used a qPCR to detect 
and quantify S pneumoniae and therefore could not 
establish the burden of viable bacteria. Nevertheless, a 
strong correlation between culture and lytA qPCR in 
quantifying S pneumoniae is reported.27 Although we 
provide an effect of LAIV on the overall pneumococcal 
population, analysing the effect on specific PCV and 
non-PCV S pneumoniae serotypes would be important. 
We also observed an association between higher day 7 
LAIV shedding and greater pneumococcal density at 
that timepoint. This is in keeping with a hypothesis that 
greater viral burden might drive more bacterial proli-
feration, whether due to higher viral load of a single virus 
or co-infections with several viruses. However, as both 
LAIV and S pneumoniae quantification was done by 
means of a single swab, we cannot exclude that this 
association was an artefact of variability in sample 
material collected with each swab.
Our study was not powered to detect a difference in 
pneumococcal carriage rates between groups. However, 
we did observe an increase in pneumococcal colonisation 
over time in the LAIV group. It was not possible for us to 
establish whether this was due to an increase in pre-
existing S pneumoniae below the level of detection of our 
qPCR assay or new acquisitions. Of note, human co-
challenge study in adults has observed that receipt of 
LAIV 3 days before pneumococcal challenge increased 
the S pneumoniae carriage prevalence detected by 
molecular methods (60% compared with 40% in 
controls).11 Our study was also not designed to establish 
how long the effect of either LAIV or other acute 
respiratory viral infections on pneumococcal density 
might last. We did not know when the asymptomatic 
respiratory viruses detected at baseline might have 
occurred. An LAIV challenge study with longer follow-up 
or a longitudinal cohort study characterising the effect 
of asymptomatic and symptomatic respiratory viral 
infections on bacterial dynamics would be valuable.
We did an individually randomised study, which 
theoretically might underestimate the effect on children 
in the control group as higher pneumococcal densities in 
vaccinated children might increase transmission in 
shared environments. Although this might be an issue 
when recruiting from day care centres,9,10 it is less likely 
to be relevant in our community-based study in which 
young children spend most days within and around their 
own households. We recruited 20 sibling pairs, with only 
six pairs in which one sibling was in the LAIV group and 
the other in the control group during the same year. 
Finally, we were unable to fully explain the unexpected 
increase in pneumococcal density between days 7 and 21 
in control group participants recruited in 2018 which 
confounded our comparisons between groups.
The Gambia introduced PCV into its Expanded 
Programme of Immunisation in 2009 with nonavalent 
PCV (PCV9) and switched to 13-valent (PCV13) in 2011.28 
By 2014, PCV13 coverage in children under 12 months 
was 94%.29 Despite vaccine-attributed reduction of 
pneu mococcal pneumonia and invasive pneumococcal 
disease,28,29 S pneumoniae carriage remains high with 
concurrent rapid replacement of PCV-serotypes by non-
vaccine serotypes.30 Our findings represent, to the best of 
our knowledge, the first data elucidating interactions 
between both LAIV and naturally-acquired asymptomatic 
viral infections on pneumococcal density in children 
from an area of high pneumococcal carriage in Africa. 
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Introduction of LAIV and other respiratory virus vaccines 
might be key to curb the burden of RTIs caused by 
both viruses and bacteria in LMICs. Although the 
effect of widespread LAIV rollout in settings with high 
pneumococcal burden on transmission of S pneumoniae 
has not been established, our data suggest that LAIV 
behaves like any other asymptomatic viral infection. 
Considering that LAIV has a wealth of safety data in 
young children and was well tolerated and highly 
accepted in our study,13 these findings should provide 
further support around use of LAIV in African countries 
to urgently reduce the substantial burden of influenza 
mobidity and mortality that exists in young children.
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